Most recently, preliminary results from phase II clinical trials evaluating the safety and efficacy of hepcidin mimetic rusfertide (PTG-300) in phlebotomy-requiring PV patients demonstrate a virtual elimination of phlebotomy requirements, control of RBC count, increase in systemic iron stores, and a potential decrease in systemic symptoms (Hoffman, 2021; Hoffman et al., 2022; Ginzburg et al., 2021). This evidence concerns the gene HAMP and acquired polycythemia vera.